Concord Biotech Limited vs Fortis Healthcare Limited
Last updated: 22 October 2026
MoneyDock presents a comparative analysis between Concord Biotech Limited (CONCORDBIO.NS) and Fortis Healthcare Limited (FORTIS.NS), two significant players in India's healthcare and pharmaceutical sectors. While Concord Biotech specializes in the research, development, manufacturing, and marketing of biopharmaceutical products, Fortis Healthcare operates a network of hospitals, diagnostics centers, and daycare facilities, offering a broad spectrum of healthcare services. Both companies cater to critical aspects of public health, making them intriguing subjects for investors looking to gain exposure to India's growing healthcare economy. This comparison will delve into their recent financial performance, market stability, and potential attractiveness for different investor profiles based on the provided metrics.
Key Financial Metrics Comparison
| Metric | Concord Biotech Limited | Fortis Healthcare Limited |
|---|---|---|
| Current Price | ₹1270.70 | ₹726.65 |
| 52-Week High | ₹1579.40 | ₹990.35 |
| 52-Week Low | ₹1014.80 | ₹726.65 |
| 1-Year Return | -7.88% | -16.95% |
| Trailing P/E | N/A | N/A |
| Market Cap | N/A | N/A |
Analysis: Valuation, Returns, and Stability
Valuation: With both companies showing 'N/A' for Trailing P/E and Market Cap, a direct valuation comparison based on these metrics is not possible. However, looking at the current price, Concord Biotech is trading at ₹1270.70, significantly higher than Fortis Healthcare's ₹726.65. This doesn't necessarily indicate better or worse valuation without earnings or market capitalization data, but it does show Concord Biotech as a higher-priced stock per share.
Returns: In terms of 1-Year Returns, Concord Biotech Limited has performed better, albeit still negative, with a -7.88% return compared to Fortis Healthcare Limited's -16.95%. This suggests that Concord Biotech has been more resilient in the past year, experiencing a smaller decline in value. For investors focused on recent performance, Concord Biotech holds an advantage here.
Stability: To assess stability, we can look at the proximity of the current price to the 52-week low. Fortis Healthcare's current price of ₹726.65 is exactly its 52-week low. This could indicate a current bottoming out or significant recent downward pressure, potentially making it appear less stable in the short term, or conversely, presenting an attractive entry point if a rebound is anticipated. Concord Biotech's current price of ₹1270.70 is well above its 52-week low of ₹1014.80, suggesting less immediate downside risk from its recent performance bottom compared to Fortis. The gap between the 52-week high and low is also notable: Concord Biotech (₹1579.40 - ₹1014.80 = ₹564.60 range) and Fortis Healthcare (₹990.35 - ₹726.65 = ₹263.70 range). While Concord Biotech has a wider price fluctuation range over the year, Fortis's current price being at its 52-week low could signal greater recent instability or a correction.
MoneyDock Verdict
MoneyDock Verdict
For Aggressive Investors: Fortis Healthcare might pique interest due to its current price sitting exactly at its 52-week low. This could be seen as an aggressive 'buy the dip' opportunity, assuming a strong belief in its recovery. The higher risk, higher reward potential is inherent here.
For Conservative Investors: Concord Biotech appears to be the more conservative choice between the two, primarily because its 1-year return, while negative, is significantly better than Fortis Healthcare's. Its current price also offers a buffer from its 52-week low, suggesting potentially less immediate downside risk compared to Fortis.
For Long-Term SIP Investors: Given the limited data (especially missing P/E and Market Cap), it's challenging to make a definitive long-term call. However, for a long-term SIP approach, both companies operate in critical sectors with long-term growth potential in India. Concord Biotech's stronger relative 1-year performance might make it slightly more appealing for consistent investment, indicating better resilience. For Fortis, a long-term SIP would hinge on a strong conviction in its ability to rebound from its current 52-week low and capitalize on the growing demand for healthcare services.
Price data from Yahoo Finance. AI analysis by MoneyDock. Not financial advice — always do your own research before investing.